Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.
Biodesix Inc (BDSX) delivers innovative diagnostic solutions through advanced blood-based testing for lung disease and oncology. This news hub provides investors and healthcare professionals with essential updates on corporate developments, clinical advancements, and strategic partnerships.
Access real-time updates on earnings announcements, FDA clearances, clinical trial results, and biopharmaceutical collaborations. Our curated collection ensures you stay informed about critical developments in molecular diagnostics and precision medicine without needing to track multiple sources.
Key updates include:
• Financial performance reports
• Diagnostic test approvals
• Research partnership announcements
• Clinical study outcomes
Bookmark this page for streamlined access to verified Biodesix news. Combine regular monitoring with in-depth analysis of how these developments impact the diagnostic solutions landscape.
Biodesix (Nasdaq: BDSX), a leading diagnostic solutions company focusing on lung disease, has announced its participation in two upcoming investor conferences in September 2024. The company's management team will be presenting at:
1. Lake Street Capital Markets 8th Annual Best Ideas Growth Conference on September 12, 2024, at The Yale Club in New York, NY. CEO Scott Hutton will be presenting.
2. Colorado BioScience Association (CBSA) Rocky Mountain Life Sciences Investor and Partnering Conference from September 12-13, 2024, at Beaver Run Resort & Conference Center in Breckenridge, CO. CFO Robin Cowie will be presenting.
These presentations offer opportunities for investors to gain insights into Biodesix's operations, strategies, and potential growth prospects in the diagnostic solutions sector, particularly in lung disease diagnostics.
Biodesix (NASDAQ: BDSX) reported strong Q2 2024 results, with revenue growing 51% year-over-year to $17.9 million. The company's gross profit margin improved to 78.4%, up 5.7% from Q2 2023. Biodesix raised its full-year 2024 revenue guidance to $70-72 million from $65-68 million. Q2 2024 saw improvements in net loss (19%) and Adjusted EBITDA (38%) compared to Q2 2023. Lung Diagnostic test volume grew 42% year-over-year to 13,900. The company's cash position strengthened to $42.2 million, bolstered by a $55 million offering. Biodesix continues to focus on its five on-market lung diagnostic tests and improving profitability.
Biodesix (Nasdaq: BDSX), a leading diagnostic solutions company focusing on lung disease, has announced its participation in Canaccord Genuity's 44th Annual Growth Conference. The event is scheduled for August 13-14, 2024, at the InterContinental Boston, MA.
CEO Scott Hutton will represent Biodesix in a fireside chat on Wednesday, August 14, 2024, at 1:00 PM ET. Additionally, the company will host in-person 1x1 investor meetings during the conference. Investors and interested parties can access a live webcast of the presentation through the 'News & Events' section of Biodesix's website, with a replay option available afterwards.
This participation underscores Biodesix's commitment to engaging with the investment community and showcasing its advancements in lung disease diagnostics.
Biodesix (Nasdaq: BDSX), a leading diagnostic solutions company, has announced it will release its second quarter 2024 financial results on August 7, 2024, after the market closes. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a general business update. Interested parties can register for the webcast online, and analysts wishing to participate in the Q&A session should use a separate link. A replay of the webcast will be available on Biodesix's investor website approximately two hours after the call concludes. Participants are advised to join 15 minutes before the start time.
Biodesix (Nasdaq: BDSX) has been named to Inc. Magazine’s 2024 Best Workplaces list. The accolade results from an in-depth, data-driven process identifying American companies with exceptional workplace cultures. Biodesix, a diagnostic solutions leader, was one of 543 honorees selected from thousands of submissions. The recognition follows a comprehensive employee survey by Quantum Workplace, focusing on management effectiveness, perks, recognition, and overall culture. Founded in 2006, Biodesix reported high double-digit revenue growth and a 93% employee engagement score. CEO Scott Hutton emphasized the company's commitment to a culture of excellence.
Biodesix, a diagnostic solutions company specializing in lung disease, has announced its participation in two investor conferences in June 2024. CEO Scott Hutton will present at the William Blair 44th Annual Growth Stock Conference on June 4 in Chicago, IL, at 10:40 AM CT. He will also present at the Jefferies Global Healthcare Conference on June 6 in New York, NY, at 8:30 AM ET. Both presentations will be webcast live and available for replay in the Investors section of Biodesix's website.
Biodesix announced that it will present new data on the Nodify XL2 test at the 2024 ATS International Conference. The data focuses on the test's ability to identify benign lung nodules in patients with emphysema. The presentation will review a subgroup analysis from the ORACLE study involving 280 patients, demonstrating high negative predictive value of the test, helping to rule out lung cancer irrespective of emphysema status. Dr. Arthur Romero from UNLV will present the findings, suggesting that the test can help avoid unnecessary procedures, thereby allowing timely emphysema treatments.
Biodesix, Inc. (Nasdaq: BDSX) announced first-quarter 2024 results showcasing total revenue of $14.8 million, a 64% year-over-year increase, and 7th consecutive quarter of >50% growth in Lung Diagnostic test volume. The company raised $55 million in gross proceeds from a public offering. Biodesix reported a record quarterly gross profit margin of 79% and a Net Loss improvement of 27%. The company aims to reach profitability by growing revenue and maintaining cost discipline.
Biodesix, Inc. (Nasdaq: BDSX) will participate in the 2024 RBCCM Global Healthcare Conference, with CEO Scott Hutton hosting investor meetings. The conference will take place from May 14-15, 2024, in New York, NY. The presentation will be webcast live and available for replay on Biodesix's website.
